Bio-Rad Laboratories, Inc.: updates and filings

BIONYSEHealthcare · Laboratory Analytical Instruments

Price

$370.17

November 18, 2026Market cap $10.1B

What Ploutos Investor adds for Bio-Rad Laboratories

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 75 daysAround Feb 1, 2027 · for Q4 2026

last Nov 4, 2026next Feb 1, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 13, 2026 latest annualNov 4, 2026 latest quarterly
  • Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 4, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Aug 4, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 4, 2026Results of operations, restructuring costs, Regulation FD disclosure
    Form8-K
  • May 13, 2026Conflict minerals report
    FormSD
  • Apr 30, 2026Shares registered for employees
    FormS-8
  • Apr 30, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • Apr 30, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Apr 24, 2026Officer or director change, shareholder vote
    Form8-K
  • Mar 26, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Mar 25, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Mar 25, 2026Annual meeting proxy statement
    FormDEF 14A
  • Feb 19, 2026Regulation FD disclosure
    Form8-K
  • Feb 13, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Feb 12, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Oct 30, 2025Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Oct 30, 2025Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Oct 29, 2025Quarterly reportfor the period to Sep 30, 2025
    Form10-Q
  • Oct 29, 2025Results of operations, Regulation FD disclosure
    Form8-K
  • Oct 28, 2025Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Oct 28, 2025Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Oct 17, 2025Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Sep 30, 2025Regulation FD disclosure
    Form8-K
  • Aug 26, 2025Regulation FD disclosure
    Form8-K
  • Aug 6, 2025Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 29, 1994.

The full analysis

What do Bio-Rad Laboratories's filings show?

The filings are where every one of Bio-Rad Laboratories's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.